Skip to main content

Research News

 

Clinical courses

  • Protein interaction causing rare but deadly vaccine-related clotting found

    A mechanism that led some patients to experience cases of deadly clotting following some types of Covid-19 vaccination has been identified in new research.

    In a recent paper published in Blood, scientists from the University of Birmingham funded by the National Institute for Health and Care Research and the British Heart Foundation have been able to identify how deadly blood clots, in the disease known as Vaccine-Induced Immune Thrombocytopenia and Thrombosis (VITT), occur.

  • Breakthrough T Cell Discovery Has Huge Potential for Engineering Custom Immune Responses

    T cells are soldiers on the front lines of the human immune system. They are responsible for many important roles, including attacking viral- or bacterial-infected cells and certain cancer cells, and immunological memory – remembering the specific pathogens or the cancer signatures that originally trigger T cells.

  • Psoriasis not caused by spontaneous mutations in skin cells

    Psoriasis - a chronic skin condition - is not caused or spread by spontaneous genetic mutations in the skin, new research suggests. The team, from the Wellcome Sanger Institute and collaborators, sequenced skin samples from 111 people with psoriasis. They didn’t find any mutated genes in the psoriatic patches that weren’t also mutated in the individual’s unaffected skin tissue.

  • Eisai shows trial results for LEQEMBI

    Eisai Co., Ltd and Biogen Inc. announced today that Eisai presented new data for LEQEMBI® (lecanemab-irmb) 100 mg/mL injection for intravenous (IV) use, in the Late Breaking Symposium 4 Lecanemab for Early Alzheimer's Disease: Long-Term Outcomes, Predictive Biomarkers and Novel Subcutaneous Administration" at the 16th annual Clinical Trials on Alzheimer's Disease (CTAD) conference held in Boston, Massachusetts, United States and virtually October 24-27, 2023.

  • New Study Demonstrates Promise of Engineering Gut Bacteria to Treat Hypertension

    Scientists at The University of Toledo have proven that engineered bacteria can lower blood pressure, a finding that opens new doors in the pursuit of harnessing our body’s own microbiome to treat hypertension. The study, published this month in the peer-reviewed journal Pharmacological Research, represents a paradigm shift, said Dr. Bina Joe, a hypertension researcher at UToledo and the paper’s senior author.

  • Certain Per and Polyfluoroalkyl Forever Chemicals Identified as Potential Risk Factor for Thyroid Cancer

    Mount Sinai researchers have discovered a link between certain per- and polyfluoroalkyl substances (PFAS) and an increased risk for thyroid cancer, according to a study published in eBioMedicine today.

  • First Ever Dengue pill knocking roll-out door

    The Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) announced today promising data from a Phase 2a human challenge study evaluating JNJ-1802, a first-in-class oral antiviral in development for the prevention of dengue. The data showed that the compound induced antiviral activity against dengue (DENV-3) in humans, compared to placebo, and is safe and well-tolerated. The data were announced at the American Society of Tropical Medicine & Hygiene Annual Meeting in Chicago, Illinois.

  • Two Probiotics Identified as Promising Hypertension Treatments

    An estimated 40% of the global adult population have high blood pressure, or hypertension, which puts people at risk of cardiovascular disease and other dangerous health conditions. Recent studies suggest that probiotics may offer a protective effect, but researchers have a limited understanding of why shaping the gut microbiota can regulate blood pressure.

  • Magnetic gel that heals diabetic wounds three times faster

    Diabetic patients, whose natural wound-healing capabilities are compromised, often develop chronic wounds that are slow to heal. Such non-healing wounds could cause serious infections resulting in painful outcomes such as limb amputation. To address this global healthcare challenge, a team of researchers from the National University of Singapore (NUS) engineered an innovative magnetic wound-healing gel that promises to accelerate the healing of diabetic wounds, reduce the rates of recurrence, and in turn, lower the incidents of limb amputations.

  • Breakthrough in treatment for world’s leading cause of kidney failure in children

    A potential treatment for the world’s leading cause of kidney failure in children needing dialysis has been discovered by an international team of scientists.

Subscribe to Research News